Navigation Links
Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications
Date:6/29/2009

a, "In just over a year from incorporation in Hong Kong, Pangu BioPharma has demonstrated how well the government, university and industry partnership works. In that short time, with the support of HKUST and funding from the ITC, we have attracted a highly skilled group of scientists, established a well quipped lab at HKUST with the latest technology, and built an IP generating platform at the Pangu BioPharma operations that has already yielded data to support three new patent applications. These inventions are key components of aTyr Pharma's product generating engine, and are proof of the strong support Pangu BioPharma receives from the Hong Kong government and HKUST."

Professor Paul Schimmel of The Scripps Research Institute is a visiting scholar at the Institute of Advanced Science at HKUST and a co-founder of aTyr Pharma as well as Pangu BioPharma. Professor Schimmel was the driver behind building the partnership between aTyr and HKUST. An expert on tRNA synthetases, Paul Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, Repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as companies that develop and market new medicines. "This is an exciting time to launch a biotechnology endeavor in Hong Kong. The government and university system in Hong Kong have a powerful vision to translate their strengths in research into a thriving biotechnology industry that opens the door to the valuable resources of China. aTyr Pharma and Pangu BioPharma are at the forefront of this effort and are pleased to have the ITC and HKUST as partners. We particularly value the contributions of Professors Mingjie Zhang and Nancy Ip of the Biochemistry Department at HKUST, as well as Matthew Yuen of HKUST's Research and Development group," says Professor Schi
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
8. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4
... 16, 2007 - Somanta,Pharmaceuticals (OTCBB:SMPM) today announced ... presented later today at the American,Association for ... The poster presentation is entitled "Cytotoxicity of ... Excision,Repair and DNA Mismatch Repair defects," and ...
... Second Half of 2007 -, BRISBANE, Australia, April ... the final stage 1,results of its Phase 2 ... surgical removal of liver cancer. The 48 week,data ... improvement in,disease-free rate, the primary endpoint, of 25 ...
Cached Medicine Technology:Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
(Date:9/1/2014)... involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) are ... where issues related to claims involving the pain reliever ... Bernstein Liebhard LLP reports. , According to a ... the meeting is scheduled to take place on September ... of several Tylenol conferences that have taken place this ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Developers of FCPX ... tutorial video for the ProWorld Plugin from Pixel Film Studios. ... Pro X can do and users now have the ability ... Said Christina Austin, CEO of Pixel Film Studios. “Blurring the ... changer.” , Learn how to turn a 2D HDRI image ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
... ... recorder prior to offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital ... professionals and everyday consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in ...
... has proved surprisingly effective at binding to the DNA of ... minutes. The DNA binding properties of the compound were first ... Warwick by Professor Mike Hannon and Professor Alison Rodger (Professor ... the strength of its antibiotic powers have now made it ...
... Widely Expressed on Tumors and Tumor Blood Vessel Cells ... Inc., a subsidiary of Eisai Corporation of North America, ... cleared its investigational new drug (IND) application to study ... MORAb-004 targets endosialin, a protein expressed on cells associated ...
... Will Increase by a Modest $300 Million From 2008 to ... , WALTHAM, Mass., June 9 Decision Resources, one ... and healthcare issues, finds that growth in the Parkinson,s disease ... through 2018, will be offset by generic erosion of key ...
... in Four Locations to Hold Discussions on Aging in Place ... , WASHINGTON, June 9 As part of a ... in America will be hosting workshops throughout the month of ... older Americans remain in their communities. , , ...
... America, Inc. (OTC Bulletin Board: CPCF), announced today that its ... application to the MedClose(TM) Vascular Closure System (VCS) -- previously ... and basis for its new strategic plan as a Closure ... and testing of the MedClose(TM) VCS, which is an internal ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 3Health News:How Prepared are America's Communities to Handle the Aging Boom? 4Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 2Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 3Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 4
This compression garment can be used for Breast Augmentation, Augmentation Mammaplasty, Trans Umbilical Breast Augmentation, Transaxillary Submuscular Augmentation....
Bra With Cups...
Bras and Breast Support...
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication...
Medicine Products: